Literature DB >> 19481839

[Medicalisation of prevention: notes on procedures, contents and basics].

Félix Miguel García1, Alejandro Merino Senovilla, Ruperto Sanz Cantalapiedra, Alejandra García Ortiz, María José Montero Alonso, José Angel Maderuelo Fernández.   

Abstract

Mesh：

Year:  2009        PMID： 19481839      PMCID： PMC7022099          DOI： 10.1016/j.aprim.2008.12.010

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  10 in total

1.  Clinical trial registration: a statement from the International Committee of Medical Journal Editors.

Authors:  Catherine De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusic; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

2.  All-or-nothing treatment targets make bad performance measures.

Authors:  Rodney A Hayward
Journal:  Am J Manag Care       Date:  2007-03       Impact factor: 2.229

3.  [Limits to the power of medicine to define disease and risk factor, and quarternary prevention].

Authors:  Juan Gérvas; Mercedes Pérez Fernández
Journal:  Gac Sanit       Date:  2006-12       Impact factor: 2.139

4.  Impugning the integrity of medical science: the adverse effects of industry influence.

Authors:  Catherine D DeAngelis; Phil B Fontanarosa
Journal:  JAMA       Date:  2008-04-16       Impact factor: 56.272

Review 5.  Narrative review: the promotion of gabapentin: an analysis of internal industry documents.

Authors:  Michael A Steinman; Lisa A Bero; Mary-Margaret Chren; C Seth Landefeld
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

6.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.

Authors:  Judith A Whitworth
Journal:  J Hypertens       Date:  2003-11       Impact factor: 4.844

7.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

8.  Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: a case study based on documents from rofecoxib litigation.

Authors:  Bruce M Psaty; Richard A Kronmal
Journal:  JAMA       Date:  2008-04-16       Impact factor: 56.272

9.  Medical journals are an extension of the marketing arm of pharmaceutical companies.

Authors:  Richard Smith
Journal:  PLoS Med       Date:  2005-05-17       Impact factor: 11.069

10.  Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group.

Authors:  David Atkins; Martin Eccles; Signe Flottorp; Gordon H Guyatt; David Henry; Suzanne Hill; Alessandro Liberati; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger Schünemann; Tessa Tan-Torres Edejer; Gunn E Vist; John W Williams
Journal:  BMC Health Serv Res       Date:  2004-12-22       Impact factor: 2.655
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.